Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model

Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors

(2015) Sarah A. Holstein et al.   INVESTIGATIONAL NEW DRUGS

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

(2014) Yoshihiko Ichikawa et al.   JOURNAL OF CLINICAL INVESTIGATION

The role of antioxidants in the era of cardio-oncology

(2013) Duncan T. Vincent et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Anthracyclines and Heart Failure

(2013) Douglas B. Sawyer   NEW ENGLAND JOURNAL OF MEDICINE

Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells

(2013) Anna Vavrova et al.   PLoS One

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE